fda glp-1 warning letters november 2025 The has received hundreds of adverse event reports tied to compounded GLP-1s. PRI's brief warns that patients should know the risks before trusting knockoff versions. Read the brief: https://medecon.org/unauthorized-glp-1-knockoffs FDA in Flux — February
Description
Furthermore, pancreatic ductal adenocarcinoma and pancreatic intraepithelial neoplasia, both associated with pancreatic cancer development, express GLP-1R, while normal pancreatic ductal cells and acini demonstrate proliferative responses to GLP-1RAs, suggesting that incretin-based medications may induce specific proliferative changes in the islets

Its important for patients to maintain a balanced diet and exercise routine to optimize results during this period

In 2023, that number was $71.7bn, a 500% increase, according to a report in the medical journal Jama

This is why following storage guidelines is not just about safety